Powered by Max Banner Ads 

Medical news from PWRM, LIFE, and IDRA

crwefinancelogo2

signup3m

POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM) is now available for $0.0321 cents a share. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. A breakout could be an indicator of possible momentum.

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops.

PWRM is a leader in bio-medical research and the commercialization of biomarkers, tests, and mechanisms of disease. Power3′s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, and to identify protein biomarkers and drug targets, to fulfill critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro).

Idera Pharmaceuticals (Nasdaq:IDRA) recently reported that it has received commitments from certain institutional investors to purchase approximately $15 million of securities in a registered direct offering. Idera expects to receive net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

In the offering Idera has agreed to sell approximately 4.0 million units, each unit consisting of one share of common stock and a warrant to purchase 0.40 of a share of common stock. The units will be sold at a price of $3.71, which price was calculated based on the closing bid price of the Company’s common stock on July 30, 2010. The warrants will be exercisable at a price of $3.71 per share beginning immediately and will expire five years from the date that the warrants are issued. The offering is expected to close by August 5, 2010, subject to customary closing conditions.

IDRA develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Their proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses.

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading shares for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).

About the Author